480 related articles for article (PubMed ID: 16099700)
1. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.
Ellis-Grosse EJ; Babinchak T; Dartois N; Rose G; Loh E; ;
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S341-53. PubMed ID: 16080072
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan.
Chuang YC; Chang CM; Aradhya S; Nagari B; Pai V; Dartois N; Jouve S; Cooper A
J Microbiol Immunol Infect; 2011 Apr; 44(2):116-24. PubMed ID: 21439514
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.
Breedt J; Teras J; Gardovskis J; Maritz FJ; Vaasna T; Ross DP; Gioud-Paquet M; Dartois N; Ellis-Grosse EJ; Loh E;
Antimicrob Agents Chemother; 2005 Nov; 49(11):4658-66. PubMed ID: 16251309
[TBL] [Abstract][Full Text] [Related]
6. Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective.
Teras J; Gardovskis J; Vaasna T; Kupcs U; Pupelis G; Dukart G; Dartois N; Jouve S; Cooper A;
J Chemother; 2008 Oct; 20 Suppl 1():20-7. PubMed ID: 19036671
[TBL] [Abstract][Full Text] [Related]
7. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.
Corey GR; Wilcox M; Talbot GH; Friedland HD; Baculik T; Witherell GW; Critchley I; Das AF; Thye D
Clin Infect Dis; 2010 Sep; 51(6):641-50. PubMed ID: 20695801
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
Grolman DC
Int J Infect Dis; 2007 May; 11 Suppl 1():S7-15. PubMed ID: 17603950
[TBL] [Abstract][Full Text] [Related]
11. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Tanaseanu C; Bergallo C; Teglia O; Jasovich A; Oliva ME; Dukart G; Dartois N; Cooper CA; Gandjini H; Mallick R; ;
Diagn Microbiol Infect Dis; 2008 Jul; 61(3):329-38. PubMed ID: 18508226
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.
Babinchak T; Ellis-Grosse E; Dartois N; Rose GM; Loh E; ;
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S354-67. PubMed ID: 16080073
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.
Gardiner D; Dukart G; Cooper A; Babinchak T
Clin Infect Dis; 2010 Jan; 50(2):229-38. PubMed ID: 20025527
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections.
Noel GJ; Bush K; Bagchi P; Ianus J; Strauss RS
Clin Infect Dis; 2008 Mar; 46(5):647-55. PubMed ID: 18225981
[TBL] [Abstract][Full Text] [Related]
16. Tigecycline: a review of a new glycylcycline antibiotic.
Scheinfeld N
J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
[TBL] [Abstract][Full Text] [Related]
17. Tigecycline: a novel broad-spectrum antimicrobial.
Slover CM; Rodvold KA; Danziger LH
Ann Pharmacother; 2007 Jun; 41(6):965-72. PubMed ID: 17519296
[TBL] [Abstract][Full Text] [Related]
18. Tigecycline: a novel glycylcycline antibiotic.
Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
[TBL] [Abstract][Full Text] [Related]
19. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections.
Sader HS; Mallick R; Kuznik A; Fritsche TR; Jones RN
Int J Antimicrob Agents; 2007 Dec; 30(6):514-20. PubMed ID: 17959359
[TBL] [Abstract][Full Text] [Related]
20. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
Wilcox MH; Tack KJ; Bouza E; Herr DL; Ruf BR; Ijzerman MM; Croos-Dabrera RV; Kunkel MJ; Knirsch C
Clin Infect Dis; 2009 Jan; 48(2):203-12. PubMed ID: 19072714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
